



MOFFITT
CANCER CENTER

Cell Therapies Liason Meeting

21 October 2010

Co-Chairs:

- William Janssen, ISCT*
- Phyllis Warkentin, FACT*

What are we talking about?


- “Regulation of Mobilized Peripheral Blood”
 - Multiple misnomers in this title:
 - Blood is not mobilized – Hematopoietic Progenitor Cells (HPC) Are
 - When HPC are mobilized, they are still in the blood stream, and thus in the sole possession of, the donor – not subject to regulation – need to be collected first
 - What we really are talking about then, is mobilized HPC collected from peripheral blood with the intention of performing a transplant

Presentations to address

- What has been learned about transplant of mobilized HPC under the NMDPs IND
- Management of Donors, particularly donor safety
 - NMDP overview
 - View from vantage point of apheresis director

Mobilized HPC for transplant (view from my lab...)

RELATED DONOR



Donor risk / benefit

Donor safety
assessment

Genetic disparity
donor-recipient

Extracorporeal time
Management of product
environmental
conditions

Risk to recipient:
unmanipulated product
vs. manipulated (e.g.
plasma depletion for
minor mismatch)

Data in hand / data
yet to be collected
(final sterility
culture) result

UNRELATED DONOR

